The neurobiology and treatment of first-episode schizophrenia

被引:164
|
作者
Kahn, R. S. [1 ]
Sommer, I. E. [1 ]
机构
[1] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Psychiat, NL-3584 CX Utrecht, Netherlands
关键词
MAGNETIC-RESONANCE SPECTROSCOPY; ULTRA-HIGH RISK; DRUG-NAIVE PATIENTS; DOPAMINE SYNTHESIS CAPACITY; C-REACTIVE PROTEIN; DORSOLATERAL PREFRONTAL CORTEX; MATERNAL IMMUNE ACTIVATION; NMDA RECEPTOR HYPOFUNCTION; HIGH-AFFINITY STATE; HIGH GENETIC RISK;
D O I
10.1038/mp.2014.66
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It is evident that once psychosis is present in patients with schizophrenia, the underlying biological process of the illness has already been ongoing for many years. At the time of diagnosis, patients with schizophrenia show decreased mean intracranial volume (ICV) as compared with healthy subjects. Since ICV is driven by brain growth, which reaches its maximum size at approximately 13 years of age, this finding suggests that brain development in patients with schizophrenia is stunted before that age. The smaller brain volume is expressed as decrements in both grey and white matter. After diagnosis, it is mainly the grey matter loss that progresses over time whereas white matter deficits are stable or may even improve over the course of the illness. To understand the possible causes of the brain changes in the first phase of schizophrenia, evidence from treatment studies, postmortem and neuroimaging investigations together with animal experiments needs to be incorporated. These data suggest that the pathophysiology of schizophrenia is multifactorial. Increased striatal dopamine synthesis is already evident before the time of diagnosis, starting during the at-risk mental state, and increases during the onset of frank psychosis. Cognitive impairment and negative symptoms may, in turn, result from other abnormalities, such as NMDA receptor hypofunction and low-grade inflammation of the brain. The latter two dysfunctions probably antedate increased dopamine synthesis by many years, reflecting the much earlier presence of cognitive and social dysfunction. Although correction of the hyperdopaminergic state with antipsychotic agents is generally effective in patients with a first-episode psychosis, the effects of treatments to correct NMDA receptor hypofunction or low-grade inflammation are (so far) rather modest at best. Improved efficacy of these interventions can be expected when they are applied at the onset of cognitive and social dysfunction, rather than at the onset of psychosis.
引用
收藏
页码:84 / 97
页数:14
相关论文
共 50 条
  • [21] Dissecting the Heterogeneity of Treatment Response in First-Episode Schizophrenia
    Malhotra, Anil K.
    SCHIZOPHRENIA BULLETIN, 2015, 41 (06) : 1224 - 1226
  • [22] Happiness in first-episode schizophrenia
    Agid, Ofer
    McDonald, Krysta
    Siu, Cynthia
    Tsoutsoulas, Christopher
    Wass, Caroline
    Zipursky, Robert B.
    Foussias, George
    Remington, Gary
    SCHIZOPHRENIA RESEARCH, 2012, 141 (01) : 98 - 103
  • [23] Pharmacotherapy of first-episode schizophrenia
    Remington, G
    Kapur, S
    Zipursky, RB
    BRITISH JOURNAL OF PSYCHIATRY, 1998, 172 : 66 - 70
  • [24] Values in First-Episode Schizophrenia
    Agid, Ofer
    McDonald, Krysta
    Fervaha, Gagan
    Littrell, Romie
    Thoma, Jessica
    Zipursky, Robert B.
    Foussias, George
    Remington, Gary
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2015, 60 (11): : 507 - 514
  • [25] Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial
    Ceskova, Eva
    Prikryl, Radovan
    Libiger, Jan
    Svancara, Jan
    Jarkovsky, Jiri
    SCHIZOPHRENIA RESEARCH, 2015, 169 (1-3) : 303 - 307
  • [26] Insight, treatment outcomes and recovery in first-episode schizophrenia
    Agid, O.
    Siu, C. O.
    Harvey, P. D.
    Zipursky, R. B.
    Remington, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S449 - S449
  • [27] OPTIMISE-ING THE TREATMENT OF FIRST-EPISODE SCHIZOPHRENIA
    Arango, Celso
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S49 - S49
  • [28] THE PSYCHOBIOLOGY OF FIRST-EPISODE SCHIZOPHRENIA
    WARING, E
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1995, 40 (07): : S33 - S37
  • [29] PREDICTING TREATMENT RESISTANT SCHIZOPHRENIA AT FIRST-EPISODE OF PSYCHOSIS
    Smart, Sophie
    Agbedjro, Deborah
    Pardinas, Antonio
    Walters, James
    Stahl, Daniel
    Murray, Robin
    MacCabe, James
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S229 - S230
  • [30] TREATMENT OUTCOMES, INSIGHT AND RECOVERY IN FIRST-EPISODE SCHIZOPHRENIA
    Agid, Ofer
    Siu, Cynthia
    Harvey, Philip D.
    Zipursky, Robert
    Fervaha, Gagan
    Foussias, George
    McDonald, Krysta
    Remington, Gary
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S165 - S166